Key result
NOACs account for ~63% of new AF prescriptions in Egypt, associated with low 12-month event rates.
Why the study?
Real-world data on AF in the Middle East and North Africa region, including Egypt, are sparse.
Observational (n=723)
Yes
In a prospective Egyptian registry of newly diagnosed NVAF, NOACs were the most commonly prescribed antithrombotic therapy, and clinical event rates at 1 year were low.
INTRODUCTION: Real-world data on atrial fibrillation (AF) in the Middle East and North Africa (MENA) region, including Egypt, are sparse. The aim of the FLOW-AF registry was to evaluate the characteristics, treatment patterns, and clinical and economic outcomes of newly diagnosed non-valvular atrial fibrillation (NVAF) patients within the MENA region, including Egypt. METHODS: This multicenter, prospective, observational registry enrolled newly diagnosed patients with NVAF from January 2020 to December 2022 at eight private-sector healthcare centers in Egypt. Data were collected at enrollment (baseline), and then at 6-month and 12-month follow-up. Baseline data included demographics, AF characteristics, medical history, and antithrombotic treatment patterns. Follow-up data included clinical events, healthcare resource utilization, and related costs. Non-vitamin K antagonist oral anticoagulants (62.52%), vitamin K antagonists (22.28%), and antiplatelet therapy (9.85%) were among the prescribed treatments. Rates of transient ischemic attack and all-cause mortality were 2.64% and 0.83%, respectively; all other outcomes (stroke, bleeding, myocardial infarction, systemic embolism) occurred at a rate of ≤ 0.41%. Antithrombotic medications were the major contributors to per-patient total yearly cost (USD 381.2). Additional research, including a broader study population with a longer follow-up, is essential to comprehensively assess the characteristics and outcomes of the NVAF population in Egypt.
No takes yet. Share an insight, caveat, or question.
Sobhy et al. (2025) conducted an observational in Non-valvular atrial fibrillation (NVAF) (n=723). Antithrombotic treatment (NOACs, VKAs, antiplatelets) was evaluated on Clinical outcomes (transient ischemic attack, all-cause mortality, stroke, bleeding, MI, systemic embolism). In newly diagnosed patients with non-valvular atrial fibrillation in Egypt, non-vitamin K antagonist oral anticoagulants were the most prescribed treatment (62.52%), with low 12-month rates of transient ischemic attack (2.64%) and all-cause mortality (0.83%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: